It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Understanding the molecular mechanisms underlying frontotemporal dementia (FTD) is essential for the development of successful therapies. Systematic studies on human post-mortem brain tissue of patients with genetic subtypes of FTD are currently lacking. The Risk and Modyfing Factors of Frontotemporal Dementia (RiMod-FTD) consortium therefore has generated a multi-omics dataset for genetic subtypes of FTD to identify common and distinct molecular mechanisms disturbed in disease. Here, we present multi-omics datasets generated from the frontal lobe of post-mortem human brain tissue from patients with mutations in MAPT, GRN and C9orf72 and healthy controls. This data resource consists of four datasets generated with different technologies to capture the transcriptome by RNA-seq, small RNA-seq, CAGE-seq, and methylation profiling. We show concrete examples on how to use the resulting data and confirm current knowledge about FTD and identify new processes for further investigation. This extensive multi-omics dataset holds great value to reveal new research avenues for this devastating disease.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 German Center for Neurodegenerative Diseases, Tübingen, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426)
2 German Center for Neurodegenerative Diseases, Tübingen, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426); National Institutes of Health, National Institute on Aging, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
3 German Center for Neurodegenerative Diseases, Göttingen, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426)
4 German Center for Neurodegenerative Diseases, Tübingen, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426); Hertie Institute for Clinical Brain Research, Tübingen, Germany (GRID:grid.428620.a)
5 University of Brescia, Neurology Unit, Department of Clinical and Experimental Sciences, Brescia, Italy (GRID:grid.7637.5) (ISNI:0000 0004 1757 1846)
6 University of Southern California, California, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)
7 German Center for Neurodegenerative Diseases, Tübingen, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426); University Medical Center Hamburg-Eppendorf, Institute of Medical Systems Biology, Hamburg, Germany (GRID:grid.13648.38) (ISNI:0000 0001 2180 3484)